is tirzepatide zepbound Now Available Through LillyDirect: A New Option for Access at a Predictable Price Lilly releases Zepbound® (tirzepatide) single-dose

Tirzepatide (Mounjaro, Zepbound) is a dual GIP/GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, but concerns about tirzepatide and thyroid nodules have emerged from animal studies showing thyroid C-cell tumors in rodents

Retatrutide Administration & Trial Dosing Once-weekly injection Clinical dosing used in trials: Final FDA-approved dosing may differ

Its mechanism preserves natural feedback, reducing the risk of hormone excess, pituitary suppression, and related side effects

Yes, rotating injection sites with each dose is recommended to allow tissue recovery and minimize cumulative irritation